Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 3rd edition

Go to Drug-Resistant Tuberculosis page

First released in 2004, the Guide is a joint publication of CITC and the Tuberculosis Control Branch of the California Department of Public Health. It contains information and user-friendly tools and templates for use by any clinician who participates in the management of patients with drug-resistant TB. 
The 10 chapters and 4 appendices cover major topics pertaining to epidemiology, diagnosis, laboratory issues, treatment, medications, pediatrics, co-morbidities and special situations, monitoring and case management, adverse reactions, and treatment of contacts.

What's new in the third edition of the Guide?

  • Laboratory, a new chapter presenting information about the laboratory tests used to confirm TB infection and/or disease, including tests available for the more rapid molecular detection of TB and drug resistance
  • New data on outcomes of treatment for drug-resistant TB and newer drugs and regimens available
  • Updated information about 23 medications used to treat tuberculosis, including 5 new fact sheets not included in the second edition:  Bedaquiline, Clarithromycin, Delamanid, Meropenem, and Rifapentine.  
  • Expanded information about diagnosing and treating TB disease and LTBI in children, now devoted to its own chapter
  • New sections on “Diabetes Mellitus” and “Solid Organ Transplant” in Chapter 7, Co-Morbidities and Special Situations
  • Updated listings of resources in the Appendices.

Date of most recent third edition updates (Chapter 6: Pediatrics, pgs 158, 162)October 2019 

Date of third edition release: April 2016

Date of second edition release: December 2008

Date of original release: June 2004